Mechanisms for regulation of cellular responsiveness to human IFN-β1a

被引:41
作者
Dupont, SA [1 ]
Goelz, S [1 ]
Goyal, J [1 ]
Green, M [1 ]
机构
[1] Biogen Inc, Cambridge, MA 02142 USA
关键词
D O I
10.1089/10799900252952280
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interferons (IFNs) are potent, pleiotropic cytokines, and therefore it is likely that the cell has mechanisms to modulate IFN activity in response to excessive or prolonged IFN exposure. To investigate this question, Jurkat T cells were exposed to IFN-beta1a in vitro. The effect of dose and frequency of IFN treatment on receptor expression, the signal transduction pathway, and biologic activity was examined. Results demonstrate that at even modest doses of IFN (60 IU/ml), cell surface expression of the IFN receptor subunit, IFNAR-1, decreased significantly, and the cells were unresponsive to further IFN treatment. More interestingly, after an initial treatment with very low concentrations of IFN (<10 IU/ml), even when receptor levels remained normal and phosphorylation of signaling molecules occurred, cells were still refractory to further IFN treatment. After withdrawal of IFN, full cellular responsiveness was a progressive but surprisingly slow process. Cells retreated 2 days or 4 days after the initial IFN treatment were still refractory to even high doses (500 IU/ml) of IFN. Cells retreated 1 week after the initial IFN treatment were fully responsive. High levels of Stat1 and Stat2 correlated with the block in transcriptional activation of IFN-dependent genes and may be a mechanism by which cells can downmodulate an IFN response. Similar results were obtained when fresh peripheral blood mononuclear cells (PBMC) were treated with IFN and expression of the endogenous IFN-dependent gene, MxA, was examined. Cell surface levels of IFNAR-1 decreased and Stat1 levels increased after IFN-beta treatment, and retreatment with IFN resulted in an attenuated induction of Mx protein expression. In the context of using IFNs as therapeutic agents in the treatment of human disease, our data suggest that increasing the amount or frequency of IFN administration may not yield desired biologic effects. Thus, issues concerning the dosage and the frequency of IFN-beta administration deserve careful consideration.
引用
收藏
页码:491 / 501
页数:11
相关论文
共 41 条
  • [1] Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers
    Alam, J
    Goelz, S
    Rioux, P
    Scaramucci, J
    Jones, W
    McAllister, A
    Campion, M
    Rogge, M
    [J]. PHARMACEUTICAL RESEARCH, 1997, 14 (04) : 546 - 549
  • [2] Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN beta-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration
    Alam, J
    McAllister, A
    Scaramucci, J
    Jones, W
    Rogge, M
    [J]. CLINICAL DRUG INVESTIGATION, 1997, 14 (01) : 35 - 43
  • [3] INTERFERON-BETA TREATMENT OF HUMAN-DISEASE
    ALAM, JJ
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 1995, 6 (06) : 688 - 691
  • [4] LIGAND-INDUCED AUTOREGULATION OF IFN-GAMMA RECEPTOR-BETA CHAIN EXPRESSION IN T-HELPER CELL SUBSETS
    BACH, EA
    SZABO, SJ
    DIGHE, AS
    ASHKENAZI, A
    AGUET, M
    MURPHY, KM
    SCHREIBER, RD
    [J]. SCIENCE, 1995, 270 (5239) : 1215 - 1218
  • [5] REGULATION OF INTERLEUKIN-6 RECEPTOR EXPRESSION IN HUMAN-MONOCYTES AND HEPATOCYTES
    BAUER, J
    LENGYEL, G
    BAUER, TM
    ACS, G
    GEROK, W
    [J]. FEBS LETTERS, 1989, 249 (01): : 27 - 30
  • [6] EVIDENCE THAT TYPE-I AND TYPE-II INTERFERONS HAVE DIFFERENT RECEPTORS
    BRANCA, AA
    BAGLIONI, C
    [J]. NATURE, 1981, 294 (5843) : 768 - 770
  • [7] CELADA A, 1987, J IMMUNOL, V139, P147
  • [8] Expression of the transcription factor STAT-1α in insulinoma cells protects against cytotoxic effects of multiple cytokines
    Chen, GX
    Hohmeier, HE
    Newgard, CB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (01) : 766 - 772
  • [9] COHEN B, 1995, MOL CELL BIOL, V15, P4208
  • [10] COLAMONICI OR, 1992, J IMMUNOL, V148, P2126